Overcoming chemotherapy drug resistance by targeting inhibitors of apoptosis proteins (IAPs)

Rama Rathore, Jennifer E. McCallum, Elizabeth Varghese, Ana Maria Florea, Dietrich Busselberg

Research output: Contribution to journalReview article

61 Citations (Scopus)

Abstract

Inhibitors of apoptosis (IAPs) are a family of proteins that play a significant role in the control of programmed cell death (PCD). PCD is essential to maintain healthy cell turnover within tissue but also to fight disease or infection. Uninhibited, IAPs can suppress apoptosis and promote cell cycle progression. Therefore, it is unsurprising that cancer cells demonstrate significantly elevated expression levels of IAPs, resulting in improved cell survival, enhanced tumor growth and subsequent metastasis. Therapies to target IAPs in cancer has garnered substantial scientific interest and as resistance to anti-cancer agents becomes more prevalent, targeting IAPs has become an increasingly attractive strategy to re-sensitize cancer cells to chemotherapies, antibody based-therapies and TRAIL therapy. Antagonism strategies to modulate the actions of XIAP, cIAP1/2 and survivin are the central focus of current research and this review highlights advances within this field with particular emphasis upon the development and specificity of second mitochondria-derived activator of caspase (SMAC) mimetics (synthetic analogs of endogenously expressed inhibitors of IAPs SMAC/DIABLO). While we highlight the potential of SMAC mimetics as effective single agent or combinatory therapies to treat cancer we also discuss the likely clinical implications of resistance to SMAC mimetic therapy, occasionally observed in cancer cell lines.

Original languageEnglish
Pages (from-to)898-919
Number of pages22
JournalApoptosis
Volume22
Issue number7
DOIs
Publication statusPublished - 1 Jul 2017

Fingerprint

Inhibitor of Apoptosis Proteins
Chemotherapy
Drug Delivery Systems
Drug Resistance
Mitochondria
Cells
Caspases
Drug Therapy
Pharmaceutical Preparations
Neoplasms
Cell death
Apoptosis
Cell Death
Therapeutics
Tumors
Cell Survival
Cell Cycle
Tissue
Neoplasm Metastasis
Antibodies

Keywords

  • Chemotherapy resistance
  • Combination therapy
  • Extrinsic apoptotic pathway
  • Inhibitors of apoptosis proteins
  • Intrinsic apoptotic pathway

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science
  • Clinical Biochemistry
  • Cell Biology
  • Biochemistry, medical
  • Cancer Research

Cite this

Overcoming chemotherapy drug resistance by targeting inhibitors of apoptosis proteins (IAPs). / Rathore, Rama; McCallum, Jennifer E.; Varghese, Elizabeth; Florea, Ana Maria; Busselberg, Dietrich.

In: Apoptosis, Vol. 22, No. 7, 01.07.2017, p. 898-919.

Research output: Contribution to journalReview article

Rathore, Rama ; McCallum, Jennifer E. ; Varghese, Elizabeth ; Florea, Ana Maria ; Busselberg, Dietrich. / Overcoming chemotherapy drug resistance by targeting inhibitors of apoptosis proteins (IAPs). In: Apoptosis. 2017 ; Vol. 22, No. 7. pp. 898-919.
@article{df5d2f1f5d3c40938517b1eb09b09aef,
title = "Overcoming chemotherapy drug resistance by targeting inhibitors of apoptosis proteins (IAPs)",
abstract = "Inhibitors of apoptosis (IAPs) are a family of proteins that play a significant role in the control of programmed cell death (PCD). PCD is essential to maintain healthy cell turnover within tissue but also to fight disease or infection. Uninhibited, IAPs can suppress apoptosis and promote cell cycle progression. Therefore, it is unsurprising that cancer cells demonstrate significantly elevated expression levels of IAPs, resulting in improved cell survival, enhanced tumor growth and subsequent metastasis. Therapies to target IAPs in cancer has garnered substantial scientific interest and as resistance to anti-cancer agents becomes more prevalent, targeting IAPs has become an increasingly attractive strategy to re-sensitize cancer cells to chemotherapies, antibody based-therapies and TRAIL therapy. Antagonism strategies to modulate the actions of XIAP, cIAP1/2 and survivin are the central focus of current research and this review highlights advances within this field with particular emphasis upon the development and specificity of second mitochondria-derived activator of caspase (SMAC) mimetics (synthetic analogs of endogenously expressed inhibitors of IAPs SMAC/DIABLO). While we highlight the potential of SMAC mimetics as effective single agent or combinatory therapies to treat cancer we also discuss the likely clinical implications of resistance to SMAC mimetic therapy, occasionally observed in cancer cell lines.",
keywords = "Chemotherapy resistance, Combination therapy, Extrinsic apoptotic pathway, Inhibitors of apoptosis proteins, Intrinsic apoptotic pathway",
author = "Rama Rathore and McCallum, {Jennifer E.} and Elizabeth Varghese and Florea, {Ana Maria} and Dietrich Busselberg",
year = "2017",
month = "7",
day = "1",
doi = "10.1007/s10495-017-1375-1",
language = "English",
volume = "22",
pages = "898--919",
journal = "Apoptosis : an international journal on programmed cell death",
issn = "1360-8185",
publisher = "Springer Netherlands",
number = "7",

}

TY - JOUR

T1 - Overcoming chemotherapy drug resistance by targeting inhibitors of apoptosis proteins (IAPs)

AU - Rathore, Rama

AU - McCallum, Jennifer E.

AU - Varghese, Elizabeth

AU - Florea, Ana Maria

AU - Busselberg, Dietrich

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Inhibitors of apoptosis (IAPs) are a family of proteins that play a significant role in the control of programmed cell death (PCD). PCD is essential to maintain healthy cell turnover within tissue but also to fight disease or infection. Uninhibited, IAPs can suppress apoptosis and promote cell cycle progression. Therefore, it is unsurprising that cancer cells demonstrate significantly elevated expression levels of IAPs, resulting in improved cell survival, enhanced tumor growth and subsequent metastasis. Therapies to target IAPs in cancer has garnered substantial scientific interest and as resistance to anti-cancer agents becomes more prevalent, targeting IAPs has become an increasingly attractive strategy to re-sensitize cancer cells to chemotherapies, antibody based-therapies and TRAIL therapy. Antagonism strategies to modulate the actions of XIAP, cIAP1/2 and survivin are the central focus of current research and this review highlights advances within this field with particular emphasis upon the development and specificity of second mitochondria-derived activator of caspase (SMAC) mimetics (synthetic analogs of endogenously expressed inhibitors of IAPs SMAC/DIABLO). While we highlight the potential of SMAC mimetics as effective single agent or combinatory therapies to treat cancer we also discuss the likely clinical implications of resistance to SMAC mimetic therapy, occasionally observed in cancer cell lines.

AB - Inhibitors of apoptosis (IAPs) are a family of proteins that play a significant role in the control of programmed cell death (PCD). PCD is essential to maintain healthy cell turnover within tissue but also to fight disease or infection. Uninhibited, IAPs can suppress apoptosis and promote cell cycle progression. Therefore, it is unsurprising that cancer cells demonstrate significantly elevated expression levels of IAPs, resulting in improved cell survival, enhanced tumor growth and subsequent metastasis. Therapies to target IAPs in cancer has garnered substantial scientific interest and as resistance to anti-cancer agents becomes more prevalent, targeting IAPs has become an increasingly attractive strategy to re-sensitize cancer cells to chemotherapies, antibody based-therapies and TRAIL therapy. Antagonism strategies to modulate the actions of XIAP, cIAP1/2 and survivin are the central focus of current research and this review highlights advances within this field with particular emphasis upon the development and specificity of second mitochondria-derived activator of caspase (SMAC) mimetics (synthetic analogs of endogenously expressed inhibitors of IAPs SMAC/DIABLO). While we highlight the potential of SMAC mimetics as effective single agent or combinatory therapies to treat cancer we also discuss the likely clinical implications of resistance to SMAC mimetic therapy, occasionally observed in cancer cell lines.

KW - Chemotherapy resistance

KW - Combination therapy

KW - Extrinsic apoptotic pathway

KW - Inhibitors of apoptosis proteins

KW - Intrinsic apoptotic pathway

UR - http://www.scopus.com/inward/record.url?scp=85018523450&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018523450&partnerID=8YFLogxK

U2 - 10.1007/s10495-017-1375-1

DO - 10.1007/s10495-017-1375-1

M3 - Review article

VL - 22

SP - 898

EP - 919

JO - Apoptosis : an international journal on programmed cell death

JF - Apoptosis : an international journal on programmed cell death

SN - 1360-8185

IS - 7

ER -